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Abstract
Background: Public health organisations use public health indicators to guide health 
policy. Joint analysis of multiple public health indicators can provide a more compre-
hensive understanding of what they are intended to evaluate.
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1  | INTRODUC TION
Public health indicators are commonly used to assess a population's 
health status. They are intended as an effective and uncomplicated 
way to compare public health between populations and over time.1,2 
Public health organisations, including the World Health Organisation 
(WHO) and the European Commission, use public health indicators 
to evaluate interventions and guide policy.3,4
Congenital anomalies are an important public health concern 
given that they are major contributors to infant mortality, morbidity 
in childhood and lifelong disability.5 The European Surveillance of 
Congenital Anomalies (EUROCAT) is a collaborative network of 43 
population-based congenital anomaly registers, based in 23 coun-
tries.6 The registries collect data on congenital anomalies occurring 
in live births, late miscarriages (20-24 weeks gestation), stillbirths 
(>24 weeks gestation), and termination of pregnancy for foetal anom-
aly (TOPFAs, any gestation). The registries each use multiple sources 
to ascertain cases and their outcomes, including hospital records 
(antenatal ultrasound, foetal medicine, cytogenetic laboratories, and 
paediatric surgery), birth and death certificates, and post-mortem 
examinations.7 Registries vary in the age up to which they ascertain 
new diagnoses, but most registries are notified of cases diagnosed 
up to at least age 1 year.7 EUROCAT surveys approximately 1.7 mil-
lion births per year in Europe, representing 29% of the European 
birth population.6
EUROCAT have developed six public health indicators that 
aim to evaluate the public health impact and assessment of inter-
ventions for congenital anomalies in Europe, using data routinely 
recorded by each registry.8 These indicators, include: (a) the prev-
alence of congenital anomaly-related perinatal mortality per 1000 
total births; (b) the prevalence of prenatal diagnosis of congenital 
anomaly per 1000 total births; (c) the prevalence of TOPFA fol-
lowing prenatal diagnosis of a congenital anomaly per 1000 total 
births; (d) Down's syndrome live birth prevalence per 1000 total 
births; (e) the prevalence of congenital anomalies requiring paedi-
atric surgery per 1000 total births; and (f) the prevalence of neural 
tube defects per 1000 total births. Previous examination of these 
indicators suggested that countries with very low TOPFA rates 
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Objective: To analyse variaitons in the prevalence of congenital anomaly-related peri-
natal mortality attributable to termination of pregnancy for foetal anomaly (TOPFA) 
and prenatal diagnosis of congenital anomaly prevalence.
Methods: We included 55 363 cases of congenital anomalies notified to 18 EUROCAT 
registers in 10 countries during 2008-12. Incidence rate ratios (IRR) representing the 
risk of congenital anomaly-related perinatal mortality according to TOPFA and pre-
natal diagnosis prevalence were estimated using multilevel Poisson regression with 
country as a random effect. Between-country variation in congenital anomaly-related 
perinatal mortality was measured using random effects and compared between the 
null and adjusted models to estimate the percentage of variation in congenital anom-
aly-related perinatal mortality accounted for by TOPFA and prenatal diagnosis.
Results: The risk of congenital anomaly-related perinatal mortality decreased as 
TOPFA and prenatal diagnosis prevalence increased (IRR 0.79, 95% confidence in-
terval [CI] 0.72, 0.86; and IRR 0.88, 95% CI 0.79, 0.97). Modelling TOPFA and prena-
tal diagnosis together, the association between congenital anomaly-related perinatal 
mortality and TOPFA prevalence became stronger (RR 0.70, 95% CI 0.61, 0.81). The 
prevalence of TOPFA and prenatal diagnosis accounted for 75.5% and 37.7% of the 
between-country variation in perinatal mortality, respectively.
Conclusion: We demonstrated an approach for analysing inter-linked public health 
indicators. In this example, as TOPFA and prenatal diagnosis of congenital anomaly 
prevalence decreased, the risk of congenital anomaly-related perinatal mortality in-
creased. Much of the between-country variation in congenital anomaly-related peri-
natal mortality was accounted for by TOPFA, with a smaller proportion accounted for 
by prenatal diagnosis.
K E Y W O R D S
perinatal mortality, termination of pregnancy for foetal anomaly
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had higher prevalence of congenital anomaly-related perinatal 
mortality, although this was not formally tested.8
Outside of the perinatal setting, previous studies have examined 
the association between several public health indicators relating to a 
range of conditions.1,9,10 However, we are not aware of any studies, 
in the perinatal setting or otherwise, that have quantified the de-
gree of variation in one indicator that may be attributable to another 
using variance explained measures in multilevel models. This ap-
proach may better explain relationships between inter-linked public 
health indicators, in all areas of research.
The aim of this study was to demonstrate a multilevel statistical 
method of analysing inter-linked public health indicators using an in-
teresting example of EUROCAT public health indicators. Using our 
proposed method, we will show how to quantify what proportion of 
between-country variation in congenital anomaly-related perinatal 
mortality may be accounted for by TOPFA prevalence. We will also 
test the hypothesis that increased TOPFA prevalence is associated 
with decreased congenital anomaly-related perinatal mortality rates.
2  | METHODS
2.1 | Data
Data on congenital anomalies notified to 18 full member EUROCAT 
registers in 10 countries between 1 January 2008 and 31 December 
2012 were included in this study (Table 1). In order to restrict our 
analysis to countries with high ascertainment of congenital anomaly-
related perinatal mortality, we used Boyle et als' approach of exclud-
ing countries where the EUROCAT infant mortality rate (in cases of 
congenital anomaly) was more than 20% lower than that reported 
by the WHO between 2005 and 2009.11 EUROCAT defines a case 
of congenital anomaly as any case with at least one diagnosis in the 
Q chapter of the WHO International Classification of Disease (ICD) 
version 10, along with a limited set of conditions coded outside the 
Q chapter: D215, D821, D1810, P350, P352, and P371. Minor anom-
alies (eg, skin tags) are excluded if they occur in isolation; further de-
tails are available in the EUROCAT Guide 1.4.12 There were 55 363 
cases with congenital anomalies notified to the 18 participating reg-
isters, which covered 2 430 440 total births during the study period. 
Indicators for the 18 registers were pooled according to country.
2.2 | Indicator definitions
The following indicators were used for each included country:
1. The prevalence of congenital anomaly-related perinatal mortal-
ity per 1000 total births: calculated as the number of cases 
with one or more congenital anomalies that resulted in foetal 
death ≥20 weeks gestational age or a death within the first 
week after birth, divided by the total number of live births 
and stillbirths in the country of interest, multiplied by 1000.
2. The prevalence of termination of pregnancy for foetal anomaly 
(TOPFA) per 1000 total births: calculated as the number of termi-
nations of a pregnancy (at any gestation) following prenatal diag-
nosis of a congenital anomaly, divided by the total number of live 
births and stillbirths in the country of interest, multiplied by 1000.
3. The prevalence of prenatal diagnosis of a congenital anomaly per 
1000 total births: defined as the number of prenatally diagnosed 
cases with a congenital anomaly divided by the total number of live 
births and stillbirths in the country of interest, multiplied by 1000.
2.3 | Statistical analysis
Prevalence rates for each indicator were calculated by country, with 
the corresponding 95% Poisson confidence intervals (CI). A null mul-
tilevel Poisson model (ie, a model with no explanatory variables) was 
fitted with congenital anomaly-related perinatal mortality preva-
lence as the outcome (or rather, with congenital anomaly-related 
perinatal mortality counts as the outcome and the log of the number 
of population births divided by 1000 as the offset) and a random ef-
fect for country, represented by the index j (Model 0):
where λ is the congenital anomaly-related perinatal mortality indicator 
that varies across countries, as represented by the index j. The variance 
term τ00 represents “baseline” variations in the prevalence of perinatal 
mortality between countries.
ln (휆)=훽0j,
훽0j= 훾00+휇0j variance (휇0j)= 휏00,
Synopsis
Study question
How can we analyse inter-linked public health indicators?
What's already known
Public health indicators are commonly used to inform 
policy decisions. Public health indicators in the same area 
are often linked, meaning variation in one indicator may be 
associated with variations in another. Nevertheless, public 
health indicators are usually considered separately.
What this study adds
Using multilevel analysis, we present a novel method for 
modelling the association between public health indicators 
that takes into account the hierarchical nature of data used 
to measure health indicators. Specifically, the method can 
be used to explore how, and the extent to which, different 
public health indicators may be related to one another.
     |  125BEST ET al.
In Model 1, the univariable association between (continuous) 
TOPFA prevalence and congenital anomaly-related perinatal mortal-
ity prevalence was modelled:
In model 2, the univariable association between (continuous) 
prenatal diagnosis of congenital anomaly prevalence and congenital 
anomaly-related perinatal mortality prevalence is modelled:
It is also possible to fit a multivariable model, in order to control 
for additional variables. To demonstrate, Model 3 was fitted with 
both our explanatory variables included:
We can now use the models to give us two different types of 
information. Firstly, γ01 and γ02 from the fixed effects part of the 
model can be interpreted as incidence rate ratios (IRRs), for example 
γ01 in model 1 can be interpreted as the relative risk of congeni-
tal anomaly-related perinatal mortality per unit increase in TOPFA 
prevalence. These show how the outcome and explanatory indica-
tors are associated, for example the IRRs in models 1 and 2 can test 
the hypothesis that the risk of congenital anomaly-related perinatal 
mortality decreases as TOPFA and prenatal diagnosis of congenital 
anomaly prevalence increase. In summary, the fixed effects can be 
used to test hypotheses about the association (linear or otherwise) 
between the outcome indicator and the explanatory indicators.
Secondly, the degree of variation in the outcome indicator that 
is “explained” by the explanatory indicator(s) can be calculated from 
the random effects part of the model. The variation between coun-
tries in the null model, which we refer to as the “baseline” variation, 
can be compared with the residual variation that remains after ad-
justing for explanatory indicators. This value can then be expressed 
as a percentage of the “baseline” variation between countries. So in 
our case, we can subtract the between-country variation after tak-
ing into account TOPFA and prenatal diagnosis of congenital anom-
aly prevalence (휏∗휓
00
) from the baseline between-country variance 
(τ00). The difference between the baseline and residual variance is 
then divided by the baseline variance in order to calculate a percent-
age of the total variance:
In this example, this statistic can be interpreted as the percent-
age of between-country variation in congenital anomaly-related 
perinatal mortality prevalence accounted for by TOPFA and prenatal 
diagnosis of congenital anomaly prevalence.
Analyses were performed in Stata 14 (using the mepoisson 
command).
2.4 | Missing data
Prenatal diagnosis data were not available for Antwerp at the time of 
analysis, and therefore, the prenatal diagnosis rate for Hainaut was 
used for Belgium. Prenatal diagnosis was not available for Dublin, and 
훽0j = 훾00+훾01TOPFA+휇0j variance (휇0j)= 휏
∗
00
.
훽0j= 훾00+훾01Prenatal diagnosis+휇0j variance (휇0j)= 휏
휓
00
.
훽0j = 훾00+훾01TOPFA+훾02Prenatal diagnosis+휇0j variance (휇0j)= 휏
∗휓
00
.
휏00−휏
∗휓
00
휏00
×100.
TA B L E  1   Prevalence of EUROCAT public health indicators, by country
Country (Registers)
Total 
births
Perinatal mortality TOPFA Prenatal diagnosis
N
Prevalence per 1000 
total births (95% CI) N
Prevalence per 1000 
total births (95% CI) N
Prevalence per 1000 
total births (95% CI)
Austria (Styria) 51 569 42 0.8 (0.6, 1.1) 197 3.8 (3.3, 4.4) 507 9.8 (9.0, 10.7)
Belgium (Antwerp, Hainaut) 170 449 153 0.9 (0.8, 1.1) 675 4.0 (3.7, 4.3) 707a 10.9 (10.1, 11.8)a
Denmark (Odense) 25 109 16 0.6 (0.4, 1.043) 172 6.9 (5.9, 8.0) 300 12.0 (10.6, 13.4)
Ireland (Dublin, SE Ireland, Cork 
and Kerry)
227 889 492 2.2 (2.0, 2.4) 38 0.2 (0.1, 0.2) 420b 4.6 (4.2, 5.1)b
Malta 21 013 66 3.1 (2.4, 4.0) 0 0 97 4.6 (3.7, 5.6)
Netherlands (N Netherlands) 87 415 91 1.0 (0.8, 1.3) 380 4.4 (3.9, 4.8) 852 9.8 (9.1, 10.4)
Norway 310 634 230 0.7 (0.7, 0.8) 1186 3.8 (3.6, 4.0) 2006 6.5 (6.2, 6.8)
Spain (Basque Country, Valencia 
Region)
344 576 165 0.5 (0.4, 0.6) 1802 5.2 (5.0, 5.5) 2894 8.4 (8.1, 8.7)
UK (Northern England, Thames 
Valley, East Midlands & South 
Yorkshire, Wales, Wessex)
1 033 724 1127 1.1 (1.0, 1.2) 5405 5.2 (5.1, 5.4) 12 252 11.9 (11.6, 12.1)
Ukraine 158 062 240 1.5 (1.3, 1.7) 539 3.4 (3.1, 3.7) 1230 7.8 (7.4, 8.2)
aPrenatal diagnosis available for Hainaut only. 
bPrenatal diagnosis available for Cork and Kerry and SE Ireland but not Dublin. 
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therefore, prenatal diagnosis prevalence for Ireland relates to Cork and 
Kerry and SE Ireland only.
2.5 | Ethics approval
Data were downloaded in aggregate form, and therefore ethical ap-
proval was not required for this study. However, each EUROCAT 
register has their own ethical approvals in place for the collection of 
data without consent.
3  | RESULTS
The prevalence of perinatal mortality in cases of congenital anoma-
lies ranged from 0.5 (95% CI 0.4, 0.6) per 1000 total births in Spain 
to 3.1 (95% CI 2.4, 4.0) per 1000 total births in Malta (Table 1). The 
prevalence of TOPFA was lowest in Malta (0 per 1000 total births) 
where TOPFA is illegal, and greatest in Denmark (6.9 per 1000 total 
births, 95% CI 5.9, 8.0) (Table 1). The prevalence of prenatal diagno-
sis of congenital anomaly ranged from 4.6 per 1000 births in both 
Malta (95% CI 3.7, 5.6) and Ireland (95% CI 4.2, 5.1) to 11.95 (95% CI 
10.6, 13.4) per 1000 total births in Denmark.
3.1 | Fixed effect associations
There was a univariable linear association between TOPFA preva-
lence and congenital anomaly-related perinatal mortality preva-
lence, with the risk of congenital anomaly-related perinatal mortality 
decreasing as TOPFA prevalence increased (Model 1, IRR 0.79, 95% 
CI 0.72, 0.86) (Figure 1). There was also a univariable linear asso-
ciation between prenatal diagnosis of congenital anomaly and con-
genital anomaly-related perinatal mortality prevalence, with the risk 
of perinatal mortality decreasing with increasing prenatal diagnosis 
prevalence (Model 2, IRR 0.88, 95% CI 0.79, 0.97; Figure 2). In model 
3, the association between congenital anomaly-related perinatal 
mortality prevalence and TOPFA prevalence strengthened after 
controlling for prenatal diagnosis prevalence (model 3, IRR 0.70, 95% 
CI 0.61, 0.81).
3.2 | Random effects
The prevalence of congenital anomaly-related perinatal mortality 
in the null model (Model 0) varied between countries with a “base-
line” between-country variance (τ00) of 0.28 (95% CI 0.11, 0.70). In 
the model including only TOPFA (Model 1), the between-country 
variation (휏∗
00
) was 0.07 (95% CI 0.03, 0.18), meaning the preva-
lence of TOPFA accounted for 75.5% of the variation in congenital 
anomaly-related perinatal mortality between countries (Table 2). In 
the model including only prenatal diagnosis only (Model 2), the be-
tween-country variation (휏휓
00
) was 0.17 (95% CI 0.07, 0.44), meaning 
the prevalence of prenatal diagnosis accounted for 37.7% of the be-
tween-country variation in perinatal mortality. In the model adjusted 
for TOPFA and prenatal diagnosis of congenital anomaly prevalence 
(Model 3), the between-country variation (휏∗휓
00
) was 0.05 (95% CI 
0.02, 0.13), meaning 83.0% of the variation in congenital anomaly-
related perinatal mortality was accounted for.
4  | COMMENT
4.1 | Principal findings
We have demonstrated a multilevel method for quantifying the de-
gree of variation in one public health indicator that is attributable 
to another. Here, TOPFA prevalence was negatively associated with 
congenital anomaly-related perinatal mortality prevalence and ac-
counted for a large percentage of between-country variation in 
perinatal mortality among babies with congenital anomalies. The 
F I G U R E  1   Actual and modelled association between perinatal 
mortality and TOPFA prevalence
F I G U R E  2   Actual and modelled association between perinatal 
mortality and prenatal diagnosis prevalence. ¥Prenatal diagnosis 
available for Hainaut only, †Prenatal diagnosis available for Cork 
and Kerry and SE Ireland but not Dublin
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prevalence of prenatal diagnosis of congenital anomalies was also 
negatively associated with congenital anomaly-related perinatal 
mortality prevalence but accounted for a smaller proportion of 
between-country variation in perinatal mortality prevalence among 
babies with congenital anomalies. These results show that it is im-
portant to understand variation in TOPFA rates when interpreting 
and comparing congenital anomaly-related perinatal mortality rates 
between countries. However, even though perinatal mortality may 
be prevented via TOPFA, the adverse birth outcome and the physical 
or emotional burden to the parents still exists and so the two indica-
tors must be considered in parallel.
4.2 | Strengths of the study
This study has several strengths. Firstly, the EUROCAT public health 
indicators we have presented are well defined, therefore satisfy-
ing an important criteria of an effective indicator.13 EUROCAT uses 
these measures as quality indicators and due to the use of mul-
tiple sources of case ascertainment they are rigorously checked. 
Congenital anomaly-related perinatal mortality is an important indi-
cator that represents the burden of mortality and acts as a marker 
for quality of prenatal screening programmes, maternity care, and 
access/uptake of health services. Additionally, our results are argu-
ably more robust because we excluded countries with potentially 
lower ascertainment of congenital anomaly-related perinatal mortal-
ity, including only countries with infant mortality rates comparable or 
higher than those reported by the WHO.11 However, in applying this 
exclusion criteria, we cannot rule out the possibility that we excluded 
data from countries with genuinely low perinatal mortality rates.
Previous methods for analysing inter-linked public health indi-
cators include presenting the indicators graphically or estimating 
only IRRs.1,14 Our proposed method allows the estimation of IRRs, 
but also provides a simple quantitative summary of the variation in 
one indicator that is attributable to one or more indicators. Although 
we have presented basic forms of the proposed technique, our ap-
proach is advantageous because it can be adapted to more complex 
scenarios. For example, we pooled the prevalence of the indicators 
by country in order to present the most simplistic form of the mul-
tilevel model. However, the prevalence also varied within country, 
for example prenatal diagnosis of congenital anomaly prevalence 
was 13.0 per 1000 in Basque Country but 6.9 per 1000 in Valencia 
Region of Spain. To account for this within country variation, we 
could have included an additional level within our multilevel model. 
A random slope could also be incorporated into the model to account 
for trends in public health indicators over time. It is also possible to 
test the hypothesis that there was a non-linear association between 
indicators by incorporating fractional polynomials or splines. There 
is scope to include further variables such as demographic informa-
tion on the study population, for example smoking rates, health 
service indicators or economic factors. It would also be possible to 
incorporate interactions between the public health indicators used 
as explanatory variables.
4.3 | Limitations of the data
There are certain caveats and limitations in our study. While we can 
assess the relation between indicators and calculate the percent-
age of variation in one indicator that may be attributable to another, 
these represent empirical associations not causal ones. Contextual 
factors including those related to data issues and various possible 
connections between indicators should be considered in interpret-
ing the statistical results from the proposed models. For example, 
we found a negative association between congenital anomaly-
related perinatal mortality prevalence and TOPFA prevalence; this 
association could be causal if severe cases of congenital anomaly 
are terminated more frequently and cannot contribute to perinatal 
mortality. Alternatively, increased termination rates may be acting 
as a proxy for improved access and/or uptake of health care or it 
could represent a more severe case mix of congenital anomalies, 
which would also influence perinatal mortality. The prevalence of 
TOPFA and congenital anomaly-related perinatal mortality may vary 
between countries due to differences in the coding of late TOPFA, 
given that some countries may code these as stillbirths as opposed 
to TOPFA. As always, any causal interpretations of the estimates 
need to be made in light of substantive knowledge of the field, in-
cluding its inherent uncertainties.
4.4 | Interpretation
We found that increased prenatal diagnosis rates were associated 
with decreased risk of congenital anomaly-related perinatal mortality. 
Countries with higher prenatal diagnosis of congenital anomaly preva-
lence had a higher prevalence of TOPFA, meaning the association 
may be mostly related to the impact of TOPFA. This is not surprising 
since prenatal diagnosis will not always result in a TOPFA but the vast 
Indicator (per 1000 births)
Fixed effects: IRR  
(95% CI)
Random effects: 
between-country 
variance (95% CI)
TOPFA (model 1) 0.79 (0.72, 0.86) 0.07 (0.03, 0.18)
Prenatal diagnosis (model 2) 0.88 (0.79, 0.97) 0.17 (0.07, 0.44)
TOPFA adjusted for prenatal diagnosis 
(model 3)
0.70 (0.61, 0.81) 0.05 (0.02, 0.13)
Abbreviations: IRR, incidence rate ratio; CI, confidence interval.
TA B L E  2   Fixed and random effects 
from models 1, 2, and 3 showing the 
associations between congenital anomaly-
related perinatal mortality prevalence 
with TOPFA and prenatal diagnosis of 
congenital anomaly prevalence
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majority of TOPFAs are likely to have been preceded by prenatal diag-
nosis. On the other hand, prenatal diagnosis of congenital anomaly can 
result in optimisation of pre- and postnatal care resulting in improved 
survival in babies with congenital anomalies. Prenatal diagnosis may 
also be a marker of improved health care access and services, which 
is thus associated with decreased congenital anomaly-related perina-
tal mortality. Individual-level data show conflicting evidence regard-
ing the association between prenatal diagnosis and mortality. Several 
studies have reported no association between prenatal diagnosis and 
post-operative survival in cases of congenital heart disease, the com-
monest type of congenital anomaly, although these are generally small 
studies that may be underpowered.15-18 Hospital-based studies have 
reported an increased risk of post-operative mortality in prenatally di-
agnosed cases of congenital heart disease, most likely because more 
severe phenotypes are diagnosed prenatally.19,20 However, in cardio-
vascular anomalies, the effect differs according to subtype.21
Additionally, we pooled the indicators over 4 years meaning 
changes in the prevalence of congenital anomaly-related perinatal 
mortality, prenatal diagnosis of congenital anomaly and TOPFA were 
averaged over time. Although we studied a relatively short study 
period (2008-12), this may have introduced some confounding of 
trends over time. With advances in prenatal diagnosis and medi-
cal and surgical interventions for congenital anomalies, congenital 
anomaly-related perinatal mortality may have decreased and the 
associations with TOPFA and prenatal diagnosis may have altered 
in more recent years. Prevalence rates for the EUROCAT public 
health indicators discussed in this paper are updated annually on the 
EUROCAT website (https ://eu-rd-platf orm.jrc.ec.europa.eu/euroc 
at/euroc at-data/key-public-health-indic ators_en).
A Canadian study also reported a negative association between 
TOPFA (occurring 20-23 weeks gestation) and infant deaths among 
cases of congenital anomaly after examining graphically their two 
indicators of interest.22 In the European population, there may be 
other differences that contribute to variation in congenital anom-
aly-related perinatal mortality, for example differences in maternal 
age, parity, and multiple births are known to influence foetal and 
neonatal deaths, although with relatively small effect sizes.23 Factors 
such as maternal smoking, alcohol use, obesity, socio-economic sta-
tus, and diabetes are also known risk factors for perinatal mortal-
ity in general and vary by European country.24-31 Additionally, we 
combined all types of congenital anomaly. Countries with a higher 
prevalence of more severe congenital anomalies but with respec-
tively lower prevalence of prenatal diagnosis or TOPFA are likely 
to have had even higher perinatal mortality than that described by 
the model.
5  | CONCLUSIONS
We have demonstrated a multilevel approach for quantifying the 
degree of variation in one public health indicator that may be at-
tributable to another. In our example, we found a negative associa-
tion between TOPFA rates and perinatal mortality among cases of 
congenital anomaly, which accounted for 75.5% of between-country 
variation. Prenatal diagnosis with TOPFA and prenatal diagnosis 
modelled together accounted for 83% of between-country variation 
in perinatal mortality.
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